WO2009149171A3 - Fgf21 mutants and uses thereof - Google Patents

Fgf21 mutants and uses thereof Download PDF

Info

Publication number
WO2009149171A3
WO2009149171A3 PCT/US2009/046113 US2009046113W WO2009149171A3 WO 2009149171 A3 WO2009149171 A3 WO 2009149171A3 US 2009046113 W US2009046113 W US 2009046113W WO 2009149171 A3 WO2009149171 A3 WO 2009149171A3
Authority
WO
WIPO (PCT)
Prior art keywords
fgf21 mutant
polypeptides
fgf21 mutants
mutant polypeptides
pharmaceutical compositions
Prior art date
Application number
PCT/US2009/046113
Other languages
French (fr)
Other versions
WO2009149171A4 (en
WO2009149171A2 (en
Inventor
Edward John Belouski
Murielle Marie Ellison
Agnes Eva Hamburger
Randy Ira Hecht
Yue-Sheng Li
Mark Leo Michaels
Jeonghoon Sun
Jing Xu
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40984291&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2009149171(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to UAA201015922A priority Critical patent/UA102395C2/en
Priority to MA34197A priority patent/MA33142B1/en
Priority to CN200980130476.4A priority patent/CN102143758B/en
Priority to JP2011512611A priority patent/JP2011523561A/en
Priority to KR1020167010524A priority patent/KR101787300B1/en
Priority to EA201001883A priority patent/EA017690B1/en
Priority to MX2012002985A priority patent/MX346396B/en
Priority to MX2010013333A priority patent/MX2010013333A/en
Priority to BRPI0911385A priority patent/BRPI0911385B8/en
Application filed by Amgen Inc. filed Critical Amgen Inc.
Priority to NZ590050A priority patent/NZ590050A/en
Priority to EP09759330.5A priority patent/EP2296690B1/en
Priority to CA2726589A priority patent/CA2726589C/en
Priority to BR122020010972-6A priority patent/BR122020010972B1/en
Priority to AU2009256232A priority patent/AU2009256232B2/en
Publication of WO2009149171A2 publication Critical patent/WO2009149171A2/en
Publication of WO2009149171A3 publication Critical patent/WO2009149171A3/en
Publication of WO2009149171A4 publication Critical patent/WO2009149171A4/en
Priority to IL209395A priority patent/IL209395A/en
Priority to TNP2010000563A priority patent/TN2010000563A1/en
Priority to ZA2010/08778A priority patent/ZA201008778B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/05—Epstein-Barr virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factors [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
PCT/US2009/046113 2008-06-04 2009-06-03 Fgf21 mutants and uses thereof WO2009149171A2 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
AU2009256232A AU2009256232B2 (en) 2008-06-04 2009-06-03 FGF21 mutants and uses thereof
EP09759330.5A EP2296690B1 (en) 2008-06-04 2009-06-03 Fgf21 mutants and uses thereof
NZ590050A NZ590050A (en) 2008-06-04 2009-06-03 Fgf21 mutants and uses thereof
CA2726589A CA2726589C (en) 2008-06-04 2009-06-03 Fgf21 mutants and uses thereof
MA34197A MA33142B1 (en) 2008-06-04 2009-06-03 FGF21 MUTANTS AND USES THEREOF
EA201001883A EA017690B1 (en) 2008-06-04 2009-06-03 Fgf21 mutants and uses thereof
MX2012002985A MX346396B (en) 2008-06-04 2009-06-03 Fgf21 mutants and uses thereof.
MX2010013333A MX2010013333A (en) 2008-06-04 2009-06-03 Fgf21 mutants and uses thereof.
BRPI0911385A BRPI0911385B8 (en) 2008-06-04 2009-06-03 isolated polypeptide, fusion polypeptide, multimer and pharmaceutical composition
UAA201015922A UA102395C2 (en) 2008-06-04 2009-06-03 Fgf21 mutants and use thereof
CN200980130476.4A CN102143758B (en) 2008-06-04 2009-06-03 Fgf21 mutant and uses thereof
KR1020167010524A KR101787300B1 (en) 2008-06-04 2009-06-03 Fgf21 mutants and uses thereof
JP2011512611A JP2011523561A (en) 2008-06-04 2009-06-03 FGF21 mutants and uses thereof
BR122020010972-6A BR122020010972B1 (en) 2008-06-04 2009-06-03 isolated and fusion polypeptide, its pharmaceutical composition and multimer
IL209395A IL209395A (en) 2008-06-04 2010-11-17 Fgf21 mutants and pharmaceutical compositions comprising them
TNP2010000563A TN2010000563A1 (en) 2009-06-03 2010-12-03 Fgf 21 mutants and uses thereof
ZA2010/08778A ZA201008778B (en) 2008-06-04 2010-12-07 Fgf21 mutants and uses thereof

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US5886108P 2008-06-04 2008-06-04
US5891908P 2008-06-04 2008-06-04
US61/058,919 2008-06-04
US61/058,861 2008-06-04
US16436409P 2009-03-27 2009-03-27
US61/164,364 2009-03-27
US17573609P 2009-05-05 2009-05-05
US61/175,736 2009-05-05

Publications (3)

Publication Number Publication Date
WO2009149171A2 WO2009149171A2 (en) 2009-12-10
WO2009149171A3 true WO2009149171A3 (en) 2010-03-11
WO2009149171A4 WO2009149171A4 (en) 2010-05-06

Family

ID=40984291

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/046113 WO2009149171A2 (en) 2008-06-04 2009-06-03 Fgf21 mutants and uses thereof

Country Status (23)

Country Link
US (9) US8034770B2 (en)
EP (1) EP2296690B1 (en)
JP (5) JP2011523561A (en)
KR (2) KR101787300B1 (en)
CN (1) CN102143758B (en)
AR (1) AR072009A1 (en)
AU (1) AU2009256232B2 (en)
BR (2) BRPI0911385B8 (en)
CA (1) CA2726589C (en)
CL (1) CL2010001346A1 (en)
CO (1) CO6341566A2 (en)
CR (1) CR11851A (en)
EA (3) EA024751B8 (en)
IL (1) IL209395A (en)
JO (1) JOP20190083A1 (en)
MA (1) MA33142B1 (en)
MX (2) MX346396B (en)
MY (1) MY152721A (en)
NZ (1) NZ590050A (en)
PE (1) PE20100253A1 (en)
SG (1) SG193860A1 (en)
TW (2) TWI403519B (en)
WO (1) WO2009149171A2 (en)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8012931B2 (en) 2007-03-30 2011-09-06 Ambrx, Inc. Modified FGF-21 polypeptides and their uses
JOP20190083A1 (en) 2008-06-04 2017-06-16 Amgen Inc Fgf21 mutant fusion polypeptides and uses thereof
SG195542A1 (en) * 2008-10-10 2013-12-30 Amgen Inc Fgf21 mutants and uses thereof
WO2010065439A1 (en) * 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
CA2760674A1 (en) 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
AR076541A1 (en) * 2009-05-05 2011-06-22 Amgen Inc MUTANTS OF FGF21 AND USES OF THE SAME
JP2012530493A (en) 2009-06-17 2012-12-06 アムジエン・インコーポレーテツド Chimeric polypeptides and uses thereof
US8889625B2 (en) * 2009-07-10 2014-11-18 Northwestern University Cardioprotective role of hepatic cells and hepatocyte secretory factors in myocardial ischemia
CN101993485B (en) * 2009-08-20 2013-04-17 重庆富进生物医药有限公司 Peptide analog homologous dimer capable of accelerating insulin secretion and application thereof
US8372952B2 (en) 2009-12-02 2013-02-12 Amgen Inc. Binding proteins that bind to human FGFR1C, human β-klotho and both human FGFR1C and human β-klotho
UA109888C2 (en) 2009-12-07 2015-10-26 ANTIBODY OR ANTIBODILITY ANTIBODY OR ITS BINDING TO THE β-CLOTE, FGF RECEPTORS AND THEIR COMPLEXES
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
EP2558497A2 (en) 2010-04-15 2013-02-20 Amgen Inc. Human fgf receptor and beta-klotho binding proteins
EP2558115B1 (en) 2010-04-16 2019-07-31 The Salk Institute for Biological Studies Methods for treating metabolic disorders using fgf
DE102010015123A1 (en) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh New benzylamidic diphenylazetidinone compounds, useful for treating lipid disorders, hyperlipidemia, atherosclerotic manifestations or insulin resistance, and for reducing serum cholesterol levels
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2012027261A1 (en) 2010-08-23 2012-03-01 Amgen Inc. Sulfonylpiperazine derivatives that interact with glucokinase regulatory protein for the treatment of diabetes
WO2012059873A2 (en) * 2010-11-05 2012-05-10 Covx Technologies Ireland, Ltd. Anti-diabetic compounds
CN102464712A (en) * 2010-11-11 2012-05-23 重庆富进生物医药有限公司 Deletion human fibroblast growth factor 21 variant and conjugate thereof
WO2012138776A1 (en) 2011-04-05 2012-10-11 Amgen Inc. Benzodioxepine and benzodioxine compounds that interact with glucokinase regulatory protein for the treatment of diabetes
US8754044B2 (en) 2011-05-03 2014-06-17 Northwestern University Neuroprotection by hepatic cells and hepatocyte secretory factors
AU2012279237B2 (en) 2011-07-01 2016-09-29 Ngm Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
WO2013033452A2 (en) 2011-08-31 2013-03-07 Amgen Inc. Method of treating or ameliorating type 1 diabetes using fgf21
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
TWI593708B (en) * 2011-09-26 2017-08-01 諾華公司 Fusion proteins for treating metabolic disorders
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
AR087973A1 (en) * 2011-10-04 2014-04-30 Lilly Co Eli VARIATIONS OF FACTOR 21 GROWTH OF FIBROBLASTS
CN102558358A (en) * 2011-12-30 2012-07-11 张海涛 Preparation and application of human fibroblast growth factor 21 fusion protein and mutant of human fibroblast growth factor 21 fusion protein
WO2013123444A1 (en) 2012-02-17 2013-08-22 Amgen Inc. Sulfonyl compounds that interact with glucokinase regulatory protein
US9475856B2 (en) 2012-03-02 2016-10-25 New York University Chimeric FGF21 proteins with enhanced binding affinity for β-klotho for the treatment of type II diabetes, obesity, and related metabolic disorders
WO2013173382A1 (en) 2012-05-15 2013-11-21 Amgen Inc. Benzothiophene sulfonamides and other compounds that interact with glucokinase regulatory protein
CN104302177B (en) 2012-05-17 2019-05-28 延伸生物科学股份有限公司 Carrier for improved drug delivery
US9464126B2 (en) 2012-06-07 2016-10-11 New York University Chimeric fibroblast growth factor 21 proteins and methods of use
US9657075B2 (en) 2012-06-07 2017-05-23 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
US9474785B2 (en) 2012-06-07 2016-10-25 New York University Chimeric fibroblast growth factor 19 proteins and methods of use
US9422353B2 (en) 2012-06-11 2016-08-23 Eli Lilly And Company Fibroblast growth factor 21 variant, composition , and uses thereof
TWI513705B (en) * 2012-06-11 2015-12-21 Lilly Co Eli Fibroblast growth factor 21 proteins
TW201420606A (en) * 2012-08-22 2014-06-01 Lilly Co Eli Homodimeric proteins
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
ES2828505T3 (en) 2012-11-28 2021-05-26 Ngm Biopharmaceuticals Inc Compositions and methods for the treatment of metabolic disorders and diseases
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
RU2675514C2 (en) 2012-12-27 2018-12-19 ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
WO2014130659A1 (en) 2013-02-22 2014-08-28 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
WO2014149699A1 (en) 2013-03-15 2014-09-25 Eli Lilly And Company Bifunctional protein
CN103191415A (en) * 2013-04-03 2013-07-10 哈尔滨博翱生物医药技术开发有限公司 Application of fibroblast growth factor-21 mature peptide in preparing medicine for treating hypertension
US20160235810A1 (en) 2013-10-18 2016-08-18 Novartis Ag Methods of treating diabetes and related disorders
CA2928135A1 (en) 2013-10-21 2015-04-30 Salk Institute For Biological Studies Mutated fibroblast growth factor (fgf) 1 and methods of use
WO2015061331A1 (en) 2013-10-21 2015-04-30 Salk Institute For Biological Studies Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use
EP3062881B1 (en) 2013-10-28 2019-10-02 NGM Biopharmaceuticals, Inc. Cancer models and associated methods
DK3097122T3 (en) 2014-01-24 2020-08-10 Ngm Biopharmaceuticals Inc ANTIBODIES BINDING BETA-KLOTHO DOMAIN 2 AND METHODS OF USING IT
WO2015138278A1 (en) 2014-03-11 2015-09-17 Novartis Ag Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling
MX2016012219A (en) 2014-03-25 2016-12-16 Regeneron Pharma Fgf21 receptor agonists and uses thereof.
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
AU2015277438B2 (en) 2014-06-16 2020-02-27 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
JP6946182B2 (en) 2014-10-22 2021-10-06 エクステンド バイオサイエンシズ インコーポレーテッドＥｘｔｅｎｄ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ Therapeutic Vitamin D Conjugate
CA2964782A1 (en) 2014-10-23 2016-04-28 Ngm Biopharmaceuticals, Inc. Pharmaceutical compositions comprising peptide variants and methods of use thereof
CN114805532A (en) 2014-10-24 2022-07-29 百时美施贵宝公司 Modified FGF-21 polypeptides and uses thereof
WO2016073855A1 (en) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
PL3236991T3 (en) 2014-12-23 2019-12-31 Novo Nordisk A/S Fgf21 derivatives and uses thereof
KR20160088656A (en) 2015-01-16 2016-07-26 주식회사유한양행 Long-acting fgf21 fusion proteins and pharmaceutical composition comprising the same
WO2016187558A2 (en) 2015-05-20 2016-11-24 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Method to improve neurologic outcomes in temperature managed patients
WO2017019957A2 (en) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
KR20170049319A (en) * 2015-10-28 2017-05-10 주식회사유한양행 Long-acting fgf21 fusion proteins and pharmaceutical composition comprising the same
KR20170049320A (en) 2015-10-28 2017-05-10 주식회사유한양행 Dual function proteins and pharmaceutical composition comprising the same
AU2016344134A1 (en) 2015-10-30 2018-05-31 Salk Institute For Biological Studies Treatment of steroid-induced hyperglycemia with fibroblast growth factor (FGF) 1 analogs
EP3377090B1 (en) 2015-11-09 2021-04-07 NGM Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
TW201731867A (en) * 2015-12-02 2017-09-16 賽諾菲公司 FGF21 variants
KR20170080526A (en) * 2015-12-31 2017-07-10 한미약품 주식회사 FGF21 Analogs, FGF21 Conjugate and use thereof
US20190142963A1 (en) * 2016-04-15 2019-05-16 Richard D. DiMarchi Fgf21 c-terminal peptide optimization
KR102483242B1 (en) 2016-08-01 2022-12-29 호프 메디신 (난징) 씨오., 엘티디. MG53 mutants and methods for their preparation and uses thereof
CN107759697B (en) 2016-08-19 2023-03-24 安源医药科技（上海）有限公司 Method for producing fusion protein
CN106279437B (en) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 Hyperglycosylated human coagulation factor VIII fusion proteins and preparation method thereof and purposes
US11123438B2 (en) 2016-08-19 2021-09-21 Ampsource Biopharma Shanghai Inc. Linker peptide for constructing fusion protein
EP3503882A4 (en) 2016-08-26 2020-07-29 NGM Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
AU2017358289A1 (en) 2016-11-10 2019-06-20 Yuhan Corporation Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins
RU2019122785A (en) 2016-12-22 2021-01-22 Санофи COMBINATIONS BASED ON FGF21 / AGONIST GLP-1R WITH AN OPTIMIZED ACTIVITY RATIO
CN108619490A (en) * 2017-03-22 2018-10-09 天士力医药集团股份有限公司 A kind of new application of the people source fibroblast growth factor of long-actingization mutation
EA201992516A1 (en) * 2017-04-21 2020-04-09 Юхан Корпорейшн METHOD FOR PRODUCING BIFUNCTIONAL PROTEINS AND THEIR DERIVATIVES
CN107056925B (en) * 2017-04-28 2022-01-14 中国科学院合肥物质科学研究院 Human FGF21 mutant, preparation method and application thereof
WO2019010314A1 (en) * 2017-07-06 2019-01-10 Yale University Compositions and methods for treating or preventing endocrine fgf-linked diseases
CN111050786A (en) 2017-09-08 2020-04-21 百时美施贵宝公司 Modified fibroblast growth factor 21(FGF-21) for use in a method of treating non-alcoholic steatohepatitis (NASH)
CN109836504B (en) * 2017-11-24 2022-08-02 浙江道尔生物科技有限公司 Multi-domain active protein for treating metabolic diseases
WO2019119673A1 (en) 2017-12-19 2019-06-27 北京吉源生物科技有限公司 Double gene-modified stem cell and use thereof
WO2019154189A1 (en) 2018-02-08 2019-08-15 Sunshine Lake Pharma Co., Ltd. Fgf21 variant, fusion protein and application thereof
BR112020026512A2 (en) 2018-07-03 2021-04-06 Bristol-Myers Squibb Company FGF-21 FORMULATIONS
US20220064244A1 (en) * 2019-03-05 2022-03-03 Sunshine Lake Pharma Co., Ltd. A polypeptide molecule and application thereof
US11427623B1 (en) 2019-05-28 2022-08-30 89Bio Ltd. Methods of treatment using mutant FGF-21 peptide conjugates
US11542309B2 (en) 2019-07-31 2023-01-03 Salk Institute For Biological Studies Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose
TW202140074A (en) 2020-01-08 2021-11-01 美商必治妥美雅史谷比公司 Fgf-21 conjugate formulations
JP7392491B2 (en) 2020-01-21 2023-12-06 トヨタ自動車株式会社 power system
EP4192495A1 (en) 2020-08-07 2023-06-14 Bristol-Myers Squibb Company Fgf21 combined with ccr2/5 antagonists for the treatment of fibrosis
WO2022115597A1 (en) 2020-11-25 2022-06-02 Bristol-Myers Squibb Company Methods of treating liver diseases
AU2022341345A1 (en) 2021-09-08 2024-03-28 Leto Laboratories Co., Ltd Fgf21 mutant protein and use thereof
CA3233918A1 (en) 2021-10-13 2023-04-20 Mariana N. Dimitrova Pharmaceutical compositions of efruxifermin
CN113980147B (en) * 2021-11-26 2023-07-28 中国药科大学 Polypeptide and FGF21 fusion protein mutant and application thereof
WO2023173021A2 (en) * 2022-03-11 2023-09-14 The Board Of Regents Of The University Of Texas System Methods and compositions for the treatment of alcohol toxicity
WO2024059507A1 (en) 2022-09-12 2024-03-21 Akero Therapeutics, Inc. Fgf21 mutant polypeptides

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005061712A1 (en) * 2003-12-10 2005-07-07 Eli Lilly And Company Muteins of fibroblast growth factor 21
WO2005091944A2 (en) * 2004-03-17 2005-10-06 Eli Lilly And Company Glycol linked fgf-21 compounds
WO2006065582A2 (en) * 2004-12-14 2006-06-22 Eli Lilly And Company Muteins of fibroblast growth factor 21

Family Cites Families (175)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (en) 1979-07-11 1985-06-05 味の素株式会社 blood substitute
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4436366A (en) 1981-02-17 1984-03-13 E. I. Du Pont De Nemours And Company End capping an optical fiber
AR230173A1 (en) 1981-06-29 1984-03-01 American Cyanamid Co INSTRUMENT FOR SURGICAL LINKS
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0133968B1 (en) 1983-07-29 1989-06-07 Mitsubishi Denki Kabushiki Kaisha Solid state overcurrent detector
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
CA1310924C (en) 1986-04-24 1992-12-01 Francis P. Mccormick Infective drug delivery system
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4970154A (en) 1987-10-09 1990-11-13 Baylor College Of Medicine Method for inserting foreign genes into cells using pulsed radiofrequency
DE3889853D1 (en) 1987-11-05 1994-07-07 Hybritech Inc Polysaccharide-modified immunoglobulins with reduced immunogenic potential or improved pharmacokinetics.
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5106627A (en) 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ATE135370T1 (en) 1988-12-22 1996-03-15 Kirin Amgen Inc CHEMICALLY MODIFIED GRANULOCYTE COLONY EXCITING FACTOR
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5288855A (en) * 1989-01-23 1994-02-22 Farmitalia Carlo Erba Extracellular form of the human fibroblast growth factor receptor
DK0481000T3 (en) * 1989-07-06 1999-11-15 Univ California Receptors for fibroblast growth factors
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
EP0779362B2 (en) 1989-12-22 2012-06-13 Laboratoires Serono SA DNA constructs for endogenous gene activation and expression modification
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
WO1991010470A1 (en) 1990-01-08 1991-07-25 Brown University Research Foundation Devices and methods for enhanced delivery of active factors
JP3068180B2 (en) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド Generation of heterologous antibodies
US5672510A (en) 1990-01-19 1997-09-30 Genetic Therapy, Inc. Retroviral vectors
WO1992000999A1 (en) 1990-07-06 1992-01-23 Rhone-Poulenc Rorer International (Holdings) Inc. Fibroblast growth factor receptors
ATE158021T1 (en) 1990-08-29 1997-09-15 Genpharm Int PRODUCTION AND USE OF NON-HUMAN TRANSGENT ANIMALS FOR THE PRODUCTION OF HETEROLOGUE ANTIBODIES
US5217889A (en) 1990-10-19 1993-06-08 Roninson Igor B Methods and applications for efficient genetic suppressor elements
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5229501A (en) * 1991-01-11 1993-07-20 Chiron Corporation Expression and use of human fibroblast growth factor receptor
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
IL100219A0 (en) 1991-12-02 1992-09-06 Yeda Res & Dev Variable region within fibroblast growth factor receptors that confers ligand specificity
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
US5234784A (en) 1992-04-01 1993-08-10 Eastman Kodak Company Method of making a projection viewable transparency comprising an electrostatographic toner image
US5364791A (en) 1992-05-14 1994-11-15 Elisabetta Vegeto Progesterone receptor having C. terminal hormone binding domain truncations
DK0646182T3 (en) * 1992-06-18 1996-09-16 Whittier Inst Diabetes & Endoc Method for Detecting Neoplastic Diseases
ES2301158T3 (en) 1992-07-24 2008-06-16 Amgen Fremont Inc. XENOGENIC ANTIBODY PRODUCTION.
US5474914A (en) 1992-07-29 1995-12-12 Chiron Corporation Method of producing secreted CMV glycoprotein H
US5489743A (en) 1993-01-19 1996-02-06 Amgen Inc. Transgenic animal models for thrombocytopenia
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
JPH11501201A (en) 1993-05-07 1999-02-02 スターリング ウィンスロップ インコーポレイティド Lactose-hydrolyzed milk and dairy products with improved taste and reduced sweetness
US6664107B1 (en) 1993-05-26 2003-12-16 Ontario Cancer Institute, University Health Network CD45 disrupted nucleic acid
CA2161015A1 (en) 1993-05-26 1994-12-08 Tak Wah Mak Transgenic mammals lacking expression of particular cd45 isoforms
US5654168A (en) 1994-07-01 1997-08-05 Basf Aktiengesellschaft Tetracycline-inducible transcriptional activator and tetracycline-regulated transcription units
US5589362A (en) 1993-06-14 1996-12-31 Basf Aktiengesellschaft Tetracycline regulated transcriptional modulators with altered DNA binding specificities
WO1994029442A2 (en) 1993-06-14 1994-12-22 Basf Aktiengesellschaft Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
CA2169292C (en) 1993-08-12 2010-11-23 E. Edward Baetge Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5484720A (en) 1994-09-08 1996-01-16 Genentech, Inc. Methods for calcium phosphate transfection
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2761116A1 (en) 1995-04-27 1996-10-31 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
AU711391B2 (en) 1995-05-26 1999-10-14 Syngenta Limited A gene switch comprising an ecdysone receptor
CA2222550A1 (en) 1995-06-07 1996-12-19 Baylor College Of Medicine Nucleic acid transporters for delivery of nucleic acids into a cell
US5849303A (en) 1995-06-07 1998-12-15 American Home Products Corporation Recombinant feline Immunodeficiency virus subunit vaccines employing baculoviral-expressed envelope glycoproteins derived from isolate NCSU-1 and their use against feline immunodeficiency virus infection
WO1996041865A1 (en) 1995-06-07 1996-12-27 Ariad Gene Therapeutics, Inc. Rapamcycin-based regulation of biological events
ATE465149T1 (en) 1996-02-28 2010-05-15 Ariad Pharma Inc SYNTHETIC RAPAMYCIN DERIVATIVES AS MULTIMERIZING AGENTS FOR CHIMERIC PROTEINS WITH IMMUNOPHILIN-DERIVED DOMAIN
JP4046354B2 (en) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Immunoglobulin-like domain with increased half-life
US5679559A (en) 1996-07-03 1997-10-21 University Of Utah Research Foundation Cationic polymer and lipoprotein-containing system for gene delivery
US6214795B1 (en) * 1996-11-12 2001-04-10 Praecis Pharmaceuticals, Inc. Peptide compounds useful for modulating FGF receptor activity
ATE355371T1 (en) * 1996-12-26 2006-03-15 Kyowa Hakko Kogyo Kk PROTEIN HAVING AN ACTIVITY OF SUPPRESSING AGING
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
ATE397063T1 (en) 1997-11-25 2008-06-15 Genentech Inc FIBROBLAST GROWTH FACTOR-19
US6150098A (en) 1998-02-20 2000-11-21 Amgen Inc. Methods for identifying novel secreted mammalian polypeptides
ZA200007412B (en) 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
NL1010174C1 (en) 1998-09-24 2000-03-27 Busschers Metaalbedrijf Bv Apparatus and method for bending tubular and rod-shaped material.
US6548634B1 (en) * 1998-09-30 2003-04-15 Chiron Corporation Synthetic peptides having FGF receptor affinity
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6369109B1 (en) 1998-10-28 2002-04-09 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Betulinic acid and derivatives thereof useful for the treatment of neuroectodermal tumor
WO2000027885A1 (en) 1998-11-05 2000-05-18 Kyowa Hakko Kogyo Co., Ltd. Novel chimeric polypeptide
AU3224700A (en) 1999-02-08 2000-08-25 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
CA2367375A1 (en) 1999-03-15 2000-09-21 Chiron Corporation Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
CA2311201A1 (en) 1999-08-05 2001-02-05 Genset S.A. Ests and encoded human proteins
US7408047B1 (en) * 1999-09-07 2008-08-05 Amgen Inc. Fibroblast growth factor-like polypeptides
US7459540B1 (en) * 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
AU7368100A (en) 1999-09-10 2001-04-10 Curagen Corporation Fibroblast growth factor polypeptide and nucleic acids encoding same
WO2001032678A1 (en) 1999-11-05 2001-05-10 Smithkline Beecham Corporation sbgFGF-19a
US6254671B1 (en) 1999-11-15 2001-07-03 Engelhard Corporation Very green-shade yellow metallized disazo pigment
US6716626B1 (en) 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
ATE446365T1 (en) 1999-11-18 2009-11-15 Novartis Vaccines & Diagnostic HUMAN FGF-21 GENE AND GENE EXPRESSION PRODUCTS
AU1628101A (en) 1999-11-22 2001-06-04 Millennium Pharmaceuticals, Inc. Jaffa, a novel fibroblast growth factor family member and uses therefor
US7108984B2 (en) * 2000-01-12 2006-09-19 Mount Sinai School Of Medicine Methods of identifying modulators of the FGF receptor
US20020081663A1 (en) 2000-01-05 2002-06-27 Conklin Darrell C. Novel FGF homolog ZFGF11
AU2631001A (en) 2000-01-05 2001-07-16 Zymogenetics Inc. Novel fgf homolog zfgf11
AU5056501A (en) 2000-03-31 2001-10-08 Nobuyuki Itoh Fibroblast growth factor-like molecules and uses thereof
JP2002112772A (en) 2000-07-10 2002-04-16 Takeda Chem Ind Ltd New polypeptide and its dna
IL139380A0 (en) 2000-10-31 2001-11-25 Prochon Biotech Ltd Active variants of fibroblast growth factor
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
US20060223114A1 (en) * 2001-04-26 2006-10-05 Avidia Research Institute Protein scaffolds and uses thereof
US20040018499A1 (en) 2001-06-06 2004-01-29 Lal Preeti G Extracellular messengers
EP1423428B2 (en) 2001-06-20 2012-11-14 Fibron Ltd. Antibodies that block fgfr3 activation, methods of screening for and uses thereof
ATE468862T1 (en) 2001-07-11 2010-06-15 Maxygen Inc G-CSF CONJUGATES
WO2003011213A2 (en) 2001-07-30 2003-02-13 Eli Lilly And Company Method for treating diabetes and obesity
US20050187150A1 (en) * 2001-10-31 2005-08-25 New York University Structure-based design and synthesis of FGF inhibitors and FGF modulator compounds
JP2005519891A (en) 2002-01-15 2005-07-07 イーライ・リリー・アンド・カンパニー Methods to reduce morbidity and mortality in critically ill patients
EP1332761A1 (en) * 2002-01-31 2003-08-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Agonists of fibroblast growth factor receptors (FGFR)
WO2003063893A2 (en) * 2002-01-31 2003-08-07 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Fgfr agonists
IL149562A0 (en) * 2002-05-09 2002-11-10 Prochon Ltd Fgf variants and methods for use thereof
JP2003334088A (en) 2002-05-22 2003-11-25 Pharma Design Inc HUMAN-DERIVED NEW Klotho-LIKE PROTEIN AND ITS GENE
AU2003265057A1 (en) 2002-09-04 2004-03-29 Abtech Anti-idiotypic antibodies as vegf or fgf agonists for bone therapy
JP2006515747A (en) 2002-11-01 2006-06-08 ジェネンテック・インコーポレーテッド Compositions and methods for the treatment of immune related diseases
WO2004056865A2 (en) 2002-12-20 2004-07-08 Enkam Pharmaceuticals A/S Method of modulation of interaction between receptor and ligand
TWI300430B (en) 2003-01-10 2008-09-01 Ritek Corp Optical recording medium dye and optical recording medium using thereof
WO2004083381A2 (en) 2003-03-13 2004-09-30 Indiana University Advanced Research & Technology Institute Fibroblast growth factor receptor-1 polynucleotides, polypeptides, and mutants
JP2006240990A (en) 2003-05-15 2006-09-14 Kirin Brewery Co Ltd Klotho protein and anti-klotho protein antibody and use of them
CN101974090B (en) 2003-06-12 2015-06-17 伊莱利利公司 GLP-1 analog fusion proteins
DK1641483T3 (en) 2003-06-12 2008-06-02 Lilly Co Eli Fusion Proteins
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP4049723B2 (en) 2003-09-04 2008-02-20 沖電気工業株式会社 Nitride semiconductor device manufacturing method and nitride semiconductor device manufacturing apparatus
DE602004032370D1 (en) 2003-10-16 2011-06-01 Imclone Llc FIBROBLAST GROWTH FACTOR 1 HEMMER AND TREATMENT METHOD THEREFOR
AU2004312376A1 (en) 2003-12-19 2005-07-21 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
US20090111742A1 (en) 2004-01-26 2009-04-30 Alexei Kharitonenkov Use of fgf-21 and thiazolidinedione for treating type 2 diabetes
JP4505631B2 (en) 2004-03-31 2010-07-21 独立行政法人産業技術総合研究所 Heparin-binding protein with heparan sulfate sugar chain added, method for producing the same, and pharmaceutical composition containing the same
EP2194064A1 (en) 2004-05-13 2010-06-09 Eli Lilly & Company FGF-21 fusion proteins
EP1789442B1 (en) 2004-09-02 2009-09-30 Eli Lilly And Company Muteins of fibroblast growth factor 21
EP1789443A1 (en) 2004-09-02 2007-05-30 Eli Lilly And Company Muteins of fibroblast growth factor 21
CA2582149C (en) 2004-10-07 2017-02-07 The Regents Of The University Of California Analogs of shk toxin and their uses in selective inhibition of kv1.3 potassium channels
EP3061461A1 (en) 2004-10-29 2016-08-31 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
US20080261875A1 (en) 2005-01-21 2008-10-23 Eli Lilly And Company Method For Treating Cardiovascular Disease
US20060193299A1 (en) * 2005-02-25 2006-08-31 Cicso Technology, Inc., A California Corporation Location-based enhancements for wireless intrusion detection
JP2006246823A (en) 2005-03-11 2006-09-21 Kyoto Univ Use of fgf21 as hematopoietic factor
WO2006130527A2 (en) 2005-05-31 2006-12-07 Novartis Ag Mutations and polymorphisms of fibroblast growth factor receptor 1
CA2614039C (en) * 2005-07-22 2015-10-13 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
AU2006280321A1 (en) 2005-08-15 2007-02-22 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
US7395962B2 (en) 2005-10-28 2008-07-08 United Parcel Service Of America, Inc. Pick up notice and method of using same
US8043833B2 (en) 2005-10-31 2011-10-25 Novo Nordisk A/S Expression of soluble therapeutic proteins
WO2007056789A1 (en) 2005-11-16 2007-05-24 Dier Corporation As Trustee For The Reid Family Superannuation Trust New frame assemblies for security screens
CA2644046A1 (en) 2006-02-28 2007-09-07 Trustees Of Boston University Metabolic regulators and uses thereof
WO2007110079A2 (en) * 2006-03-29 2007-10-04 Enkam Pharmaceuticals A/S Targeted delivery of fgfr ligands into the brain
US8101721B2 (en) 2006-06-15 2012-01-24 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
US20080274958A1 (en) * 2006-07-21 2008-11-06 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
US8969532B2 (en) * 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
EP2094850B1 (en) 2006-12-01 2013-06-12 Agency for Science, Technology And Research Cancer-related protein kinases
US8012931B2 (en) 2007-03-30 2011-09-06 Ambrx, Inc. Modified FGF-21 polypeptides and their uses
ES2665996T3 (en) * 2007-04-02 2018-04-30 Genentech, Inc. Klotho-beta agonist antibody for use in the treatment of diabetes mellitus or insulin resistance
WO2008123625A1 (en) 2007-04-06 2008-10-16 National Institute Of Advanced Industrial Science And Technology Method for activating receptor by cofactor and method for utilizing ligand activity
US7537903B2 (en) 2007-04-23 2009-05-26 Board Of Regents, The University Of Texas System FGF21 upregulates expression of GLUT-1 in a βklotho-dependent manner
WO2008135993A1 (en) 2007-05-08 2008-11-13 Tel Hashomer Medical Research Infrastructure And Services Ltd. Klotho protein and related compounds for the treatment and diagnosis of cancer
KR20100017169A (en) 2007-05-22 2010-02-16 노파르티스 아게 Methods of treating, diagnosing and detecting fgf21-associated disorders
US8481497B2 (en) 2007-05-29 2013-07-09 Sapporo Medical University Therapeutic agent for cancer, and method for treatment of cancer
US20110177029A1 (en) 2007-06-04 2011-07-21 Novo Nordisk A/S O-linked glycosylation using n-acetylglucosaminyl transferases
EP3260129A1 (en) 2007-08-03 2017-12-27 Eli Lilly and Company An fgf-21 compound and a glp-1 compound for use in the treatment of obesity
WO2009020602A2 (en) 2007-08-08 2009-02-12 Foster-Miller, Inc. Watercraft drogue system
US8426396B2 (en) 2008-01-08 2013-04-23 Shriners Hospitals For Children Treatment for achondroplasia
TW200936156A (en) * 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
WO2009117622A2 (en) 2008-03-19 2009-09-24 Ambrx, Inc. Modified fgf-23 polypeptides and their uses
JOP20190083A1 (en) 2008-06-04 2017-06-16 Amgen Inc Fgf21 mutant fusion polypeptides and uses thereof
WO2010006214A1 (en) 2008-07-09 2010-01-14 Ambrx, Inc. Fgf-21 neutralizing antibodies and their uses
US8338569B2 (en) 2008-08-04 2012-12-25 Five Prime Therapeutics, Inc. FGFR extracellular domain acidic region muteins
SG195542A1 (en) * 2008-10-10 2013-12-30 Amgen Inc Fgf21 mutants and uses thereof
CA2760674A1 (en) * 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
AR076541A1 (en) 2009-05-05 2011-06-22 Amgen Inc MUTANTS OF FGF21 AND USES OF THE SAME
JP2012530493A (en) 2009-06-17 2012-12-06 アムジエン・インコーポレーテツド Chimeric polypeptides and uses thereof
CN102656266B (en) 2009-10-15 2016-08-03 霍夫曼-拉罗奇有限公司 There is the chimeric fibroblast growth factor of the receptor-specific of change
US8372952B2 (en) 2009-12-02 2013-02-12 Amgen Inc. Binding proteins that bind to human FGFR1C, human β-klotho and both human FGFR1C and human β-klotho
UA109888C2 (en) 2009-12-07 2015-10-26 ANTIBODY OR ANTIBODILITY ANTIBODY OR ITS BINDING TO THE β-CLOTE, FGF RECEPTORS AND THEIR COMPLEXES
EP2558497A2 (en) 2010-04-15 2013-02-20 Amgen Inc. Human fgf receptor and beta-klotho binding proteins
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
AU2012279237B2 (en) 2011-07-01 2016-09-29 Ngm Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
EP2548570A1 (en) 2011-07-19 2013-01-23 Sanofi Pharmaceutical composition for treating a metabolic syndrome
WO2013033452A2 (en) 2011-08-31 2013-03-07 Amgen Inc. Method of treating or ameliorating type 1 diabetes using fgf21
RU2675514C2 (en) 2012-12-27 2018-12-19 ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005061712A1 (en) * 2003-12-10 2005-07-07 Eli Lilly And Company Muteins of fibroblast growth factor 21
WO2005091944A2 (en) * 2004-03-17 2005-10-06 Eli Lilly And Company Glycol linked fgf-21 compounds
WO2006065582A2 (en) * 2004-12-14 2006-06-22 Eli Lilly And Company Muteins of fibroblast growth factor 21

Also Published As

Publication number Publication date
AU2009256232A1 (en) 2009-12-10
BRPI0911385B1 (en) 2021-04-13
US20240076333A1 (en) 2024-03-07
SG193860A1 (en) 2013-10-30
CL2010001346A1 (en) 2011-06-03
US11072640B2 (en) 2021-07-27
CN102143758B (en) 2015-11-25
EA201270758A1 (en) 2013-12-30
EP2296690A2 (en) 2011-03-23
CN102143758A (en) 2011-08-03
TWI403519B (en) 2013-08-01
IL209395A0 (en) 2011-01-31
BRPI0911385B8 (en) 2021-09-14
JP2011523561A (en) 2011-08-18
US20090305986A1 (en) 2009-12-10
JP6960832B2 (en) 2021-11-05
MY152721A (en) 2014-11-28
EP2296690B1 (en) 2016-11-30
US8410051B2 (en) 2013-04-02
US20160168223A1 (en) 2016-06-16
EA024751B1 (en) 2016-10-31
US20190023757A1 (en) 2019-01-24
JP2021052780A (en) 2021-04-08
KR20110025810A (en) 2011-03-11
EA034847B1 (en) 2020-03-27
AR072009A1 (en) 2010-07-28
KR20160046929A (en) 2016-04-29
BR122020010972B1 (en) 2021-05-18
TW201219052A (en) 2012-05-16
US20140243503A1 (en) 2014-08-28
US11840558B2 (en) 2023-12-12
JP7191076B2 (en) 2022-12-16
WO2009149171A4 (en) 2010-05-06
KR101651697B1 (en) 2016-08-29
EA201690946A1 (en) 2017-05-31
CA2726589C (en) 2017-06-13
KR101787300B1 (en) 2017-10-18
IL209395A (en) 2014-08-31
US8034770B2 (en) 2011-10-11
US10011642B2 (en) 2018-07-03
EA024751B8 (en) 2020-01-31
CA2726589A1 (en) 2009-12-10
JP6810190B2 (en) 2021-01-06
US20120093815A1 (en) 2012-04-19
PE20100253A1 (en) 2010-04-10
US20210317176A1 (en) 2021-10-14
JP2018082699A (en) 2018-05-31
EA201001883A1 (en) 2011-06-30
MX346396B (en) 2017-03-16
US9273106B2 (en) 2016-03-01
JP6250714B2 (en) 2017-12-20
BRPI0911385A2 (en) 2019-03-26
US8642546B2 (en) 2014-02-04
MA33142B1 (en) 2012-03-01
TWI526220B (en) 2016-03-21
CR11851A (en) 2011-05-13
JP2019187417A (en) 2019-10-31
JOP20190083A1 (en) 2017-06-16
AU2009256232B2 (en) 2011-12-22
MX2010013333A (en) 2011-04-05
CO6341566A2 (en) 2011-11-21
US20120087920A1 (en) 2012-04-12
TW201010715A (en) 2010-03-16
US8361963B2 (en) 2013-01-29
US20120003216A1 (en) 2012-01-05
NZ590050A (en) 2012-08-31
WO2009149171A2 (en) 2009-12-10
EA017690B1 (en) 2013-02-28
JP2016128449A (en) 2016-07-14

Similar Documents

Publication Publication Date Title
WO2009149171A3 (en) Fgf21 mutants and uses thereof
WO2010042747A3 (en) Fgf21 mutants and uses thereof
WO2010129600A3 (en) Fgf21 mutants and uses thereof
PH12015502433A1 (en) Fgf21 mutants and uses thereof
MX2011013903A (en) Chimeric fgf19 polypeptides and uses thereof.
WO2008033413A3 (en) Albumin fusion proteins
WO2007146038A3 (en) Albumin fusion proteins
WO2009058564A3 (en) Immunosuppressive polypeptides and nucleic acids
IL202288A (en) Rsv-specific antibody or functional part thereof, nucleic acids encoding it, vectors, host cells, method for producing such antibody, compositions comprising the same and use thereof for treating rsv-related disorders
WO2007021494A3 (en) Albumin fusion proteins
WO2007059341A3 (en) Pyrazolothiazole protein kinase modulators
AP2011005814A0 (en) Gene encoding human glucokinase mutant, enzyme encoded by the same, recombinant vectors and hosts, pharmaceutical compositions and uses thereof, methods for treating and preventing diseases.
IL223076A0 (en) Novel as160-like protein, test systems, methods and uses involving it for the identification of diabetes type 2 therapeutics
UA102395C2 (en) Fgf21 mutants and use thereof
TN2011000553A1 (en) Fgf21 mutants and uses thereof
TN2010000563A1 (en) Fgf 21 mutants and uses thereof
WO2008033374A3 (en) Ocl-2a3 compositions and uses thereof
WO2008155509A9 (en) Modified human factor vii/viia and pharmaceutical composition containing same

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980130476.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09759330

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009256232

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2726589

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 7779/CHENP/2010

Country of ref document: IN

Ref document number: 12010502716

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2011512611

Country of ref document: JP

Ref document number: MX/A/2010/013333

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2009256232

Country of ref document: AU

Date of ref document: 20090603

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201011851

Country of ref document: CR

Ref document number: CR2010-011851

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 590050

Country of ref document: NZ

REEP Request for entry into the european phase

Ref document number: 2009759330

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009759330

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 201001883

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: DZP2010000799

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 10164989

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 20117000029

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A201015922

Country of ref document: UA

WWE Wipo information: entry into national phase

Ref document number: IDP00201603140

Country of ref document: ID

ENP Entry into the national phase

Ref document number: PI0911385

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20101206